1st Day: 23 April Thusday
- 09:00 - 9:15 Wellcome
Federico Garrido (Granada, Spain)
- 9:15 - 9:30 Introduction
Jean Dausset (Paris, France)
From intolerance to tolerance: a new HLA function.
SESSION I:
Chairman: Antonio Núñez-Roldán (Sevilla, Spain)
- 9:30 - 10:00 Jack L. Strominger (Cambridge, U.S.A.)
Natural killer cell lines kill autologous beta2 microglobulin
deficient melanoma cells: implications for cancer inmunotherapy.
- 10:00 - 10:30 Chella David (Rochester, U.S.A.)
HLA transgenic mice as models of human diease.
- 10:30 - 11:00 Coffee - break
- 11:00 - 11:30 Dominique Charron (Paris, France)
Inmune regulation via HLA class II molecules:
Cell activation an apoptosis.
- 11:30 - 12:00 Julia Bodmer (Oxford, England)
The world distribution of HLA types.
- 12:00 - 12:30 Peter Parham (Standford U.S.A.)
The control of human NK cells by HLA class I polymorphisms.
- 12:30 - 14:00 Lunch.
SESSION II:
Chairman: Gianni B. Ferrara (Génova, Italy)
- 14:00 - 14:30 Klass Kärre (Stockolm, Sweden)
From mosaics to crystals: studis of the NK inhibitory ligand H-2Dd.
- 14:30 - 15:00 Lorenzo Moretta (Génova, Italy)
HL class I specific inhhibitory receptosr in NK and T lymphocytes.
- 15:00 - 15:30 Miguel López Botet (Madrid, Spain)
NK cell mediated recognition of non classical HLA class I molecules.
- 15:30 - 16:00 Coffee break.
- 16:00 - 16:30 Hans-Gustaf Ljunggren (Stockholm, weden)
Triggering of NK cells.
- 16:30 - 17:00 Edgardo Corosella (Paris, France)
Role of HLA-G in NK cytolysis protection.
- 17:00 - 17:30 Marcel G.J. Tilanus (Utrech, Holland)
Molecular approaches for the detection of variable HLA
expression in tumours.
- 20:00 Concert.
2nd Day: 24 April Friday
SESSION III:
Chairman: John Hansen (Seattle, U.S.A.)
- 9:00 - 9:30 Thierry Boon (Brussels, Belgium)
Tumour antigens recognized by T lymphocytes
HLA defects in melanoma cells.
- 9:30 - 10:00 Soldano Ferrone (NY, U.S.A.)
HLA defects in melanoma cells.
- 10:00 - 10:30 Renée Fauchet (Rennes, France)
HLA-G in tumours and MHC molecules in lymphomas.
- 10:30 - 11:00 Coffee break
- 11:00 - 11:30 Rolf Kiessling (stockolm, Sweden)
T-cell epitopes from the MC1R receptor on human melanomas.
- 11:30 - 12:00 Jesper Zeuthen (Copenhagen, Denmark)
The specificity of the T-cell response and the antigenic
heterogeneity of melanoma cells.
- 12:00 - 12:30 Francesco Marincola (Bethesda, U.S.A.)
Natural variation of the expression of HLA and tumour associated
antigens in vitro and in vivo.
- 12:30 - 14:00 Lunch.
SESSION IV:
Chairman: Esteban Coelis (Rochester, U.S.A.)
- 14:00 - 14:30 Hans Schreiber (Chicago, U.S.A.)
Counteracting tumour escape: Indirectly presented,
essential tumour sepecific antigens and interferon-gamma.
- 14:30 - 15:00 Cornelis Melief (Leiden, The Netherlands)
T-cell inmunity against tumours, a delicate balance.
- 15:00 - 15:30 Peter Stern (Manchester, England)
Inmune intervention in cervical cancer.
- 15:30 - 16:00 Coffee break
- 16:00 - 16:30 Pierre Coulie (Brussels, Belgium)
CTL responses against HLA-loss variant tumour cells
- 16:30 - 17:00 Augusto C. Ochoa (New Orleans, U.S.A.)
Changes in T cell signal transduction in cancer.
- 17:00 - 17:30 Louise Koopman (eiden, The Netherlands)
Defining the molecular genetic basis of altered HLA class I
phenotypes n cervical cancer.
- 20:30 Gala dinner.
3rd. Day: 25 April Saturday
SESSION V:
Chairman: Francisco Ruiz-Cabello (Granada, Spain)
- 9:00 - 9:30 Giorgio Parmiani (milán, Italy)
Frequency of anti-melanoma/MART1 CTL precursors in melanoma
patients nd its impact in the response to inmunotheraphy.
- 9:30 - 10:00 Malclm S. Mitchell (La Jolla, CA. US.A.)
Strategies for more efficient inmunization of T cells with
melanoma epitopes.
- 10:00 - 10:30 Alex Knuth (Frankfurt, Germany)
Tumour associated peptide antigens in cancer immunotherapy.
- 10:30 - 11:00 Coffee break
- 11:00 - 11:30 Marie Marchand (Brussels, Belgium)
Clinical trials with MAGE encoded antigens.
- 11:30 - 12:00 Julio Rodríguez Villanueva Jr. (Madrid, Spain)
Apoptosis in the pathology and treatment of cancer.
- 12:00 - 13:00 Conclusions
Sir Walter Bodmer (Oxford, England)
|
TUMOR ANTIGENS AND MHC MOLECULES